Oncoplastic versus conventional breast-conserving surgery in breast cancer: a pooled analysis of 6941 female patients
Breast Cancer · 2023-03 · 30 (2) · 200-214
DOI: 10.1007/s12282-022-01430-5 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Breast Cancer, online erschienen am 09.01.2023. Verfasst von Mohammed Tarek Hasan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt. Hauptthemen laut MEDLINE: Breast Neoplasms, Mammaplasty. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 6 October University.
Abstract (Originalsprache)
Background
Breast cancer is the most prevalent cancer in women. In the past few years, surgical interventions for breast cancer have experienced massive changes from radical excision to conserving approaches. In this study, we aim to compare the two breast surgery interventions, including conventional breast-conserving surgery (CBCS) versus oncoplastic breast-conserving surgery (OPBCS).
Methods
We searched on PubMed, Web of Science (WOS), Scopus, Embase, and Cochrane till 2 October 2021. All relevant randomized controlled trials (RCTs) and observational studies were included. The data were extracted and pooled using Review Manager software (RevMan 5.4).
Results
The pooled meta-analysis of the included studies showed that OPBCS was significantly superior to CBCS in most of the outcomes. Re-excision significantly favoured CBCS (RR = 0.49, 95% CI [0.37, 0.63], P < 0.00001). However, local recurrence (RR = 0.55, 95% CI [0.27, 1.09], P = 0.09), close surgical margins (RR = 0.37, 95% CI [0.14, 1.00], P = 0.05) and end up to the risk of mastectomy (RR = 0.73, 95% CI [0.54, 97], P = 0.06) showed no significant difference between both techniques. Notably, while performing a sensitivity analysis, other outcomes as local recurrence, significantly showed favourable results towards OPBCS. In terms of safety outcomes, there was no significant difference between OPBCS and CBCS.
Conclusion
We recommend the oncoplastic approach rather than the conventional one in females with breast cancer. Re-excision rates showed better results following OPBCS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt.
- International Medical Research Association (IMedRA), Cairo, Egypt.
- Faculty of Pharmacy, Kafr El-Shaikh University, Kafr El-Shaikh, Egypt.
- Faculty of Pharmacy, Al-Azhar University-Gaza, Gaza Strip, Palestine.
- Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Faculty of Medicine, October 6 University, Cairo Governorate, Giza, 11571, Egypt. mohamedgbreel707@gmail.com.
Förderung
- 6 October University
Zitieren
APA
Hasan, M. T., Hamouda, M., Khashab, M. K. E., Elsnhory, A. B., Elghamry, A. M., Hassan, O. A., Fayoud, A. M., Hafez, A. H., Al-Kafarna, M., Hagrass, A. I., Rabea, R. K., & Gbreel, M. I. (2023). Oncoplastic versus conventional breast-conserving surgery in breast cancer: a pooled analysis of 6941 female patients. Breast Cancer, 30(2), 200-214. https://doi.org/10.1007/s12282-022-01430-5
Vancouver
Hasan MT, Hamouda M, Khashab MKE, Elsnhory AB, Elghamry AM, Hassan OA, et al. Oncoplastic versus conventional breast-conserving surgery in breast cancer: a pooled analysis of 6941 female patients. Breast Cancer. 2023;30(2):200-214. doi:10.1007/s12282-022-01430-5
BibTeX
@article{Hasan2023,
author = {Hasan, Mohammed Tarek and Hamouda, Mohamed and Khashab, Mohammad K El and Elsnhory, Ahmed Bostamy and Elghamry, Abdullah Mohamed and Hassan, Obada Atef and Fayoud, Aya Mamdouh and Hafez, Abdelrahman H and Al-Kafarna, Mohammed and Hagrass, Abdulrahman Ibrahim and Rabea, Randa Kamal and Gbreel, Mohamed Ibrahim},
title = {Oncoplastic versus conventional breast-conserving surgery in breast cancer: a pooled analysis of 6941 female patients},
journal = {Breast Cancer},
year = {2023},
volume = {30},
number = {2},
pages = {200--214},
doi = {10.1007/s12282-022-01430-5}
}
EUVIMED